Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Identifieur interne : 000054 ( PubMed/Corpus ); précédent : 000053; suivant : 000055Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Auteurs : S. Loibl ; C. Jackisch ; A. Schneeweiss ; S. Schmatloch ; B. Aktas ; C. Denkert ; H. Wiebringhaus ; S. Kümmel ; M. Warm ; S. Paepke ; M. Just ; C. Hanusch ; J. Hackmann ; J-U Blohmer ; M. Clemens ; S Dan Costa ; B. Gerber ; K. Engels ; V. Nekljudova ; G. Von Minckwitz ; M. UntchSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
Abstract
The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n=396) in comparison to the HER2- cohort.
DOI: 10.1093/annonc/mdw610
PubMed: 27831502
Links to Exploration step
pubmed:27831502Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.</title><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany; sibylle.loibl@gbg.de.</nlm:affiliation></affiliation></author><author><name sortKey="Jackisch, C" sort="Jackisch, C" uniqKey="Jackisch C" first="C" last="Jackisch">C. Jackisch</name><affiliation><nlm:affiliation>Obstetrics & Gynecology, Sana Klinikum, Offenbach, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schneeweiss, A" sort="Schneeweiss, A" uniqKey="Schneeweiss A" first="A" last="Schneeweiss">A. Schneeweiss</name><affiliation><nlm:affiliation>National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmatloch, S" sort="Schmatloch, S" uniqKey="Schmatloch S" first="S" last="Schmatloch">S. Schmatloch</name><affiliation><nlm:affiliation>Elisabeth-Krankenhaus Kassel, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Aktas, B" sort="Aktas, B" uniqKey="Aktas B" first="B" last="Aktas">B. Aktas</name><affiliation><nlm:affiliation>Department of Gynecology & Obstetrics, University Women's Hospital Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation><nlm:affiliation>Department of Pathology, University Hospital Charité, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wiebringhaus, H" sort="Wiebringhaus, H" uniqKey="Wiebringhaus H" first="H" last="Wiebringhaus">H. Wiebringhaus</name><affiliation><nlm:affiliation>Gynecology, St. Barbara-Klinik Hamm-Heessen, Hamm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kummel, S" sort="Kummel, S" uniqKey="Kummel S" first="S" last="Kümmel">S. Kümmel</name><affiliation><nlm:affiliation>Breast Unit, interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Warm, M" sort="Warm, M" uniqKey="Warm M" first="M" last="Warm">M. Warm</name><affiliation><nlm:affiliation>Breast Unit, Brustzentrum im Krankenhaus Köln-Holweide, Köln, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Paepke, S" sort="Paepke, S" uniqKey="Paepke S" first="S" last="Paepke">S. Paepke</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Just, M" sort="Just, M" uniqKey="Just M" first="M" last="Just">M. Just</name><affiliation><nlm:affiliation>Oncology, Onkologische Schwerpunktpraxis Bielefeld, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hanusch, C" sort="Hanusch, C" uniqKey="Hanusch C" first="C" last="Hanusch">C. Hanusch</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum zum Roten Kreuz, München, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hackmann, J" sort="Hackmann, J" uniqKey="Hackmann J" first="J" last="Hackmann">J. Hackmann</name><affiliation><nlm:affiliation>Breast Unit, Marien Hospital Witten, Witten.</nlm:affiliation></affiliation></author><author><name sortKey="Blohmer, J U" sort="Blohmer, J U" uniqKey="Blohmer J" first="J-U" last="Blohmer">J-U Blohmer</name><affiliation><nlm:affiliation>Women's Clinic, Klinik für Gynäkologie am Campus Charité Mitte, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Clemens, M" sort="Clemens, M" uniqKey="Clemens M" first="M" last="Clemens">M. Clemens</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Costa, S Dan" sort="Costa, S Dan" uniqKey="Costa S" first="S Dan" last="Costa">S Dan Costa</name><affiliation><nlm:affiliation>Gynecology, Universitäts-Frauenklinik, Magdeburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gerber, B" sort="Gerber, B" uniqKey="Gerber B" first="B" last="Gerber">B. Gerber</name><affiliation><nlm:affiliation>Women's Clinic, Universitäts-Frauenklinik, Rostock, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Engels, K" sort="Engels, K" uniqKey="Engels K" first="K" last="Engels">K. Engels</name><affiliation><nlm:affiliation>Pathology, Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Nekljudova, V" sort="Nekljudova, V" uniqKey="Nekljudova V" first="V" last="Nekljudova">V. Nekljudova</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Minckwitz, G" sort="Von Minckwitz, G" uniqKey="Von Minckwitz G" first="G" last="Von Minckwitz">G. Von Minckwitz</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Untch, M" sort="Untch, M" uniqKey="Untch M" first="M" last="Untch">M. Untch</name><affiliation><nlm:affiliation>Department of Gynecology and Obstetrics, HELIOS Klinikum Berlin-Buch, Berlin, Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27831502</idno><idno type="pmid">27831502</idno><idno type="doi">10.1093/annonc/mdw610</idno><idno type="wicri:Area/PubMed/Corpus">000054</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000054</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.</title><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany; sibylle.loibl@gbg.de.</nlm:affiliation></affiliation></author><author><name sortKey="Jackisch, C" sort="Jackisch, C" uniqKey="Jackisch C" first="C" last="Jackisch">C. Jackisch</name><affiliation><nlm:affiliation>Obstetrics & Gynecology, Sana Klinikum, Offenbach, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schneeweiss, A" sort="Schneeweiss, A" uniqKey="Schneeweiss A" first="A" last="Schneeweiss">A. Schneeweiss</name><affiliation><nlm:affiliation>National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schmatloch, S" sort="Schmatloch, S" uniqKey="Schmatloch S" first="S" last="Schmatloch">S. Schmatloch</name><affiliation><nlm:affiliation>Elisabeth-Krankenhaus Kassel, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Aktas, B" sort="Aktas, B" uniqKey="Aktas B" first="B" last="Aktas">B. Aktas</name><affiliation><nlm:affiliation>Department of Gynecology & Obstetrics, University Women's Hospital Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation><nlm:affiliation>Department of Pathology, University Hospital Charité, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wiebringhaus, H" sort="Wiebringhaus, H" uniqKey="Wiebringhaus H" first="H" last="Wiebringhaus">H. Wiebringhaus</name><affiliation><nlm:affiliation>Gynecology, St. Barbara-Klinik Hamm-Heessen, Hamm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kummel, S" sort="Kummel, S" uniqKey="Kummel S" first="S" last="Kümmel">S. Kümmel</name><affiliation><nlm:affiliation>Breast Unit, interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Warm, M" sort="Warm, M" uniqKey="Warm M" first="M" last="Warm">M. Warm</name><affiliation><nlm:affiliation>Breast Unit, Brustzentrum im Krankenhaus Köln-Holweide, Köln, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Paepke, S" sort="Paepke, S" uniqKey="Paepke S" first="S" last="Paepke">S. Paepke</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Just, M" sort="Just, M" uniqKey="Just M" first="M" last="Just">M. Just</name><affiliation><nlm:affiliation>Oncology, Onkologische Schwerpunktpraxis Bielefeld, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hanusch, C" sort="Hanusch, C" uniqKey="Hanusch C" first="C" last="Hanusch">C. Hanusch</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum zum Roten Kreuz, München, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hackmann, J" sort="Hackmann, J" uniqKey="Hackmann J" first="J" last="Hackmann">J. Hackmann</name><affiliation><nlm:affiliation>Breast Unit, Marien Hospital Witten, Witten.</nlm:affiliation></affiliation></author><author><name sortKey="Blohmer, J U" sort="Blohmer, J U" uniqKey="Blohmer J" first="J-U" last="Blohmer">J-U Blohmer</name><affiliation><nlm:affiliation>Women's Clinic, Klinik für Gynäkologie am Campus Charité Mitte, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Clemens, M" sort="Clemens, M" uniqKey="Clemens M" first="M" last="Clemens">M. Clemens</name><affiliation><nlm:affiliation>Women's Clinic, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Costa, S Dan" sort="Costa, S Dan" uniqKey="Costa S" first="S Dan" last="Costa">S Dan Costa</name><affiliation><nlm:affiliation>Gynecology, Universitäts-Frauenklinik, Magdeburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gerber, B" sort="Gerber, B" uniqKey="Gerber B" first="B" last="Gerber">B. Gerber</name><affiliation><nlm:affiliation>Women's Clinic, Universitäts-Frauenklinik, Rostock, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Engels, K" sort="Engels, K" uniqKey="Engels K" first="K" last="Engels">K. Engels</name><affiliation><nlm:affiliation>Pathology, Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Nekljudova, V" sort="Nekljudova, V" uniqKey="Nekljudova V" first="V" last="Nekljudova">V. Nekljudova</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Minckwitz, G" sort="Von Minckwitz, G" uniqKey="Von Minckwitz G" first="G" last="Von Minckwitz">G. Von Minckwitz</name><affiliation><nlm:affiliation>German Breast Group Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Untch, M" sort="Untch, M" uniqKey="Untch M" first="M" last="Untch">M. Untch</name><affiliation><nlm:affiliation>Department of Gynecology and Obstetrics, HELIOS Klinikum Berlin-Buch, Berlin, Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n=396) in comparison to the HER2- cohort.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27831502</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>10</Day></DateCreated><DateRevised><Year>2016</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2016</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">mdw610</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n=396) in comparison to the HER2- cohort.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with histologically confirmed breast cancer (n=1206) received 4 cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90mg/m(2) plus cyclophosphamide 600 mg/m(2) q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+ tumors. The primary endpoint was pCR defined as ypT0 ypN0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher rates of pCR were achieved in HER2+ than in HER2- tumors (57.8% vs 22.0%, p<0.0001 ), with the highest rate in the HER2+/HR- cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+ tumors, the pCR rate was 52.9%; (49.7% Pac, 56.4% nab-Pac). Grade ≥3 toxicities were significantly more common in HER2+ than in HER2- patients, with grade 3-4 diarrhea in 7.6% vs 0.9% (p<0.001) and febrile neutropenia in 6.3% vs 3.3% (p=0.023) of patients. LVEF decreases from baseline were uncommon, with 2.0% vs 0.4% of patients showing decreases to <50% along with a ≥10% decrease from baseline.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loibl</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Breast Group Neu-Isenburg, Germany; sibylle.loibl@gbg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackisch</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Obstetrics & Gynecology, Sana Klinikum, Offenbach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneeweiss</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmatloch</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Elisabeth-Krankenhaus Kassel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aktas</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gynecology & Obstetrics, University Women's Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denkert</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Hospital Charité, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiebringhaus</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gynecology, St. Barbara-Klinik Hamm-Heessen, Hamm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kümmel</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Breast Unit, interdisziplinäres Brustzentrum an den Kliniken Essen-Mitte, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warm</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Breast Unit, Brustzentrum im Krankenhaus Köln-Holweide, Köln, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paepke</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Women's Clinic, Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Just</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology, Onkologische Schwerpunktpraxis Bielefeld, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanusch</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Women's Clinic, Klinikum zum Roten Kreuz, München, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackmann</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Breast Unit, Marien Hospital Witten, Witten.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blohmer</LastName><ForeName>J-U</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Women's Clinic, Klinik für Gynäkologie am Campus Charité Mitte, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Women's Clinic, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>S Dan</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Gynecology, Universitäts-Frauenklinik, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Women's Clinic, Universitäts-Frauenklinik, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engels</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pathology, Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nekljudova</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>German Breast Group Neu-Isenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Minckwitz</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>German Breast Group Neu-Isenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Untch</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, HELIOS Klinikum Berlin-Buch, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups.</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">early breast cancer</Keyword><Keyword MajorTopicYN="N">neoadjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">pertuzumab</Keyword><Keyword MajorTopicYN="N">trastuzumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27831502</ArticleId><ArticleId IdType="pii">mdw610</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdw610</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000054 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000054 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27831502
|texte= Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27831502" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a UnivTrevesV1
| This area was generated with Dilib version V0.6.31. |  |